Showing results (101-110 of 149) with videos related to
Sort By:
Pageof 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019Costanza Paoletti, Yufeng Li, Maria C Muñiz, et al.The Pharmacogenomics Journal|February 5, 2019
Patient-provider communications about pharmacogenomic results increase patient recall of medication changesBrittany A Borden, Sang Mee Lee, Keith Danahey, et al.Cancers|September 23, 2022
Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant ImmunotherapyWen Li, Nu N Le, Natsuko Onishi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast CancerAndres Forero-Torres, Katherine E Varley, Vandana G Abramson, et al.Nature Communications|March 31, 2025
Treatment, toxicity, and mortality after subsequent breast cancer in female survivors of childhood cancerCindy Im, Hasibul Hasan, Emily Stene, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2021
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid TumorsCorey C Foster, Gini F Fleming, Theodore G Karrison, et al.Breast Cancer Research and Treatment|July 9, 2014
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastasesCarey Anders, Allison M Deal, Vandana Abramson, et al.Breast Cancer Research and Treatment|June 26, 2018
LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastasesAmanda E D Van Swearingen, Marni B Siegel, Allison M Deal, et al.Cell Reports. Medicine|November 7, 2024
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancerMichael J Campbell, Denise M Wolf, Christina Yau, et al.Nature Communications|March 28, 2024
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II studyFilipa Lynce, Candace Mainor, Renee N Donahue, et al.Pageof 15